ClinicalTrials.gg
CompletedNCT07814781Updated Sep 11, 2026

Optimizing Early Episiotomy Wound Healing

An interventional study of Beta-Sitosterol Ointment and Hydrophilic Methacrylate Gel in Episiotomy and Perineal Wound Healing, sponsored by Hamad Medical Corporation. Completed at 1 site in Qatar. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Hamad Medical Corporation · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Dec 2023, registered Sep 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This randomized controlled trial compares hydrophilic methacrylate gel versus beta-sitosterol ointment for early episiotomy wound healing. A total of 107 women who underwent mediolateral episiotomy during vaginal delivery were allocated to receive either hydrophilic methacrylate gel (n=53) or beta-sitosterol ointment (n=54). Wound outcomes were assessed by trained observers blinded to treatment allocation and by patients at two time points approximately 12 days apart. The primary outcome was the REEDA score (Redness, Edema, Ecchymosis, Discharge, Approximation). Secondary outcomes included patient-reported pain, cosmetic appearance, satisfaction, perceived treatment effectiveness, ease of application, and likelihood of recommending treatment.

Read the detailed description

Wound healing following episiotomy is a complex biological process influenced by mechanical stress, inflammatory response, tissue perfusion, and patient-related factors. This prospective randomized single-blinded controlled trial enrolled adult women who underwent mediolateral episiotomy during vaginal delivery at a tertiary care maternity hospital in Qatar. Exclusion criteria included known dermatological conditions affecting wound healing, hypersensitivity to study products, systemic inflammatory disease, chronic conditions delaying healing (e.g., coagulation disorders, diabetes, anemia with Hb \<9 g/dl), prior perineal injury, surgery, or visible lesions, or inability to attend follow-up. A total of 107 women were allocated to receive either hydrophilic methacrylate gel (n=53) or beta-sitosterol ointment (n=54).Outcome assessments were performed by trained observers blinded to treatment allocation and by patients at two time points approximately 12 days apart. Observer-assessed outcomes used the REEDA scale (Redness, Edema, Ecchymosis, Discharge, Approximation). Patient-reported outcomes included pain, cosmetic appearance, overall satisfaction, perceived treatment effectiveness, ease of application, and likelihood of recommending treatment.

02

Conditions studied

  • Episiotomy
  • Perineal Wound Healing

Keywords

  • Episiotomy
  • Wound Healing
  • Hydrophilic Methacrylate Gel
  • Beta-Sitosterol Ointment
  • REEDA Scale
  • Postpartum
03

In context

Lead sponsor

Hamad Medical Corporation is the lead sponsor of 139 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Primigravida (first pregnancy)
  • Live term singleton pregnancy
  • Underwent mediolateral episiotomy without tear during vaginal delivery
  • Adequate reading and writing literacy

Exclusion criteria

Exclusion Criteria:

  • Known dermatological conditions affecting wound healing
  • to study products
  • Systemic inflammatory disease
  • Chronic systemic disease that delays wound healing (e.g., coagulation disorders, diabetes, anemia with \<9 g/dl)
  • Prior perineal injury, surgery, or visible lesions (e.g., genital warts, hemorrhoids)
  • Inability to attend follow-up appointments
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
107 participants (actual)

Study arms

  • Active comparator
    Beta-Sitosterol Ointment

    Participants applied Beta-Sitosterol ointment to the episiotomy/perineal wound site twice daily (morning and evening) for 2 weeks.

    Drug: Beta-Sitosterol Ointment

  • Experimental
    Hydrophilic Methacrylate Gel

    Participants applied Hydrophilic methacrylate gel to the episiotomy/perineal wound site twice daily (morning and evening) for 2 weeks.

    Drug: Hydrophilic Methacrylate Gel

Interventions

  • DrugBeta-Sitosterol Ointment

    Topical ointment containing beta-sitosterol applied to the episiotomy/perineal wound site

  • DrugHydrophilic Methacrylate Gel

    Hydrophilic methacrylate-based hydrogel applied to the episiotomy/perineal wound site

06

What researchers measure

Primary outcomes

  1. Perineal Wound Healing Assessed by REEDA Scale

    Measured using the REEDA scale (Redness, Edema, Ecchymosis, Discharge, Approximation) total score, where higher scores indicate worse wound healing, assessed by trained observers blinded to treatment allocation.

    Time frame: Assessed at two time points: Day 5 postpartum and Day 12 postpartum

Secondary outcomes

  1. Complete Wound Healing (REEDA = 0) Assessed at Day 12

    Proportion of participants with a REEDA total score of 0 (no observed redness, edema, ecchymosis, discharge, or approximation abnormality) at Day 12 postpartum, assessed by trained observers blinded to treatment allocation.

    Time frame: Day 12 postpartum

  2. Patient-Reported Pain

    Patient-reported pain rated on a 5-category verbal scale (None/Mild/Moderate/Severe/Very severe), categorized as none or mild vs. moderate to very severe.

    Time frame: Day 12 postpartum

  3. Patient Satisfaction (Patient-Reported Outcome)

    Patient-reported overall satisfaction with treatment (categorized as satisfied/very satisfied vs not satisfied).

    Time frame: Day 12 postpartum

  4. Treatment Effectiveness Perception (Patient-Reported Outcome)

    Patient-reported perceived effectiveness of treatment (categorized as effective/very effective vs not effective).

    Time frame: Day 12 postpartum

  5. Perineal Cosmetic Appearance (Patient-Reported Outcome)

    Patient-reported cosmetic appearance of the perineal wound (categorized as improved somewhat/significantly vs no change or worsened).

    Time frame: Day 12 postpartum

  6. Ease of Application (Patient-Reported Outcome)

    Ease of applying the topical treatment, categorized as easy/very easy vs neutral or difficult.

    Time frame: Day 12 postpartum

  7. Likelihood of Treatment Recommendation (Patient-Reported Outcome)

    Likelihood of recommending the treatment to others (categorized as likely/definitely recommend vs neutral or unlikely).

    Time frame: Day 12 postpartum

07

Study locations

1 site
  • Al Wakra Hospital
    Doha, 3050, Qatar
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data will not be shared. De-identified data may be made available to external collaborators under a separate institutional data use agreement for specific academic purposes, but IPD is not being made available for public sharing.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Oct 2024, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2026
First posted
Sep 11, 2026
StartActual
Dec 15, 2023
Primary completionActual
Oct 8, 2024
CompletionActual
Nov 1, 2024
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07814781
Responsible party
Dr. Yehia El Khawly (Clinical Pharmacist, Hamad Medical Corporation) — Principal investigator
First posted
Sep 11, 2026
Start date
Dec 15, 2023
Primary completion
Oct 8, 2024
Completion
Nov 1, 2024
Last update
Sep 11, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion